Analytical Chemistry as a Decision Function: Characterization That Protects Discovery Quality
Analytical Chemistry as a Decision Function: Characterization That Protects Discovery Quality Visual framework: Analytical chemistry protects every discovery decision. Discovery teams often focus on chemistry and biology output: the number of compounds synthesized, the potency achieved or the speed of the next cycle. But every decision depends on analytical confidence. If compound identity, purity, structure […]
Read MoreCADD as a Decision Engine: From Virtual Screening to Designable SAR
CADD as a Decision Engine: From Virtual Screening to Designable SAR Visual framework: CADD creates a designable path before synthesis begins. Computational chemistry is sometimes introduced as a way to reduce the number of compounds that need to be synthesized. That is useful, but it is not the full value. The best CADD work creates […]
Read MoreResponsible Use of Generative AI in Medicinal Chemistry
Responsible Use of Generative AI in Medicinal Chemistry A practical framework for helping young scientists improve productivity while safeguarding intellectual property and client confidentiality Dr. Prasant DebSenior Vice President and Site Head, Noida and Greater NoidaJubilant Biosys Introduction Generative AI is rapidly changing how scientists find information, explore ideas and communicate their work. In medicinal […]
Read MoreComplex Synthesis That Keeps Discovery Moving: Libraries, Chiral Molecules and Advanced Modalities
Complex Synthesis That Keeps Discovery Moving: Libraries, Chiral Molecules and Advanced Modalities Discovery programs depend on synthesis that is both creative and practical. A compelling design hypothesis has little value if the molecule cannot be made, purified, characterized and delivered in time to influence the next experiment. Complex synthesis is therefore not a support function. […]
Read MoreThe Modern DMTA Cycle: Why MedChem Works Better When Biology, CADD and DMPK Share the Same Clock
The Modern DMTA Cycle: Why MedChem Works Better When Biology, CADD and DMPK Share the Same Clock The design–make–test–analyze (DMTA) cycle is the core engine of small molecule drug discovery, but it delivers value only when all components move in sync and data is interpreted collectively. When design is delayed by late DMPK insights, biology […]
Read MoreProtein Quality Is Program Quality: Gene-to-Structure Strategies for Better Discovery Decisions
Protein Quality Is Program Quality: Gene-to-Structure Strategies for Better Discovery Decisions High-quality protein is one of the most important foundations in drug discovery. It affects assay performance, screening reliability, biophysical measurements, crystallography and structure-based design. Poor protein quality can create false negatives, false positives, irreproducible data and misleading SAR. Protein sciences therefore influence the entire […]
Read More